THE EUROPEAN BIOTECH ACT has taken a significant step forward after the Council agreed its negotiating position on proposed legislative changes designed to strengthen biotechnology innovation across the European Union. The measures seek to modernise existing legislation governing genetically modified micro organisms and organ processing, with the aim of creating a more efficient regulatory framework while maintaining established standards for safety, transparency, and public trust.
European Biotech Act Modernises Regulatory Framework
The proposed directive accompanies the broader European Biotech Act regulation and introduces targeted amendments to existing legislation covering genetically modified micro organisms and organ processing. The objective is to accelerate the translation of biotechnology research into clinical and commercial applications by simplifying regulatory pathways for eligible products and reflecting recent scientific advances.
Under the Council’s position, certain genetically modified micro organisms that meet predefined safety standards would be eligible for an expedited regulatory procedure. The Council also proposed replacing the term “low risk genetically modified micro organisms” with “genetically modified micro organisms eligible for an expedited procedure” to avoid implying that products outside this category should automatically be considered high risk.
The Council further refined the draft legislation by aligning terminology with other European Union legislation, clarifying responsibilities between the European Commission and Member States, and reorganising provisions to support consistent implementation.
Updated Rules Reflect Advances in Organ Processing
The proposed reforms also address developments in organ transplantation. Scientific and clinical advances have increased the time that can safely elapse between organ procurement and transplantation, creating opportunities for new approaches to organ processing.
The Council clarified the distinction between autologous transplantation, where an organ is transplanted within the same individual, and transplantation between different people. Recognising that autologous procedures frequently occur in emergency settings, the revised provisions aim to ensure that surgeons are not hindered by unnecessary regulatory requirements.
Safeguards and Next Steps
The Council also proposed changes to consent requirements for genetically modified micro organisms. Rather than allowing initial marketing consent to remain valid indefinitely, as originally proposed, the revised position limits initial consent to a maximum of 10 years. Following renewal, consent would become indefinite unless specific exceptions apply.
Additional provisions clarify that processing personal data in the context of organ transplantation may be considered in the public interest where necessary to support patient safety, maintain high healthcare standards, or facilitate cross border analysis of transplant outcomes.
The proposal will now proceed to negotiations with the European Parliament once Parliament has adopted its own position, with both institutions working towards agreement on the final legislative text.
Reference
Council of the European Union. Council agrees mandate on measures to advance biotech innovation in the EU. 16 June 2026. Available at: https://www.consilium.europa.eu/en/press/press-releases/2026/06/16/council-agrees-mandate-on-measures-to-advance-biotech-innovation-in-the-eu/. Last accessed: 9 July 2026.
Featured Image: Sergii Figurnyi on Adobe Stock
- Author:
